Microbio Co., Ltd. (TPEX:4128)

Market Cap	8.82B -34.4%
Revenue (ttm)	1.89B +9.9%
Net Income	-757.75M
EPS	-1.29
Shares Out	588.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,360,646
Average Volume	1,952,328
Open	15.20
Previous Close	15.20
Day's Range	14.95 - 15.40
52-Week Range	15.00 - 30.30
Beta	0.48
RSI	31.62
Earnings Date	Mar 27, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Mic...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4128

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.